Published in PLoS One on April 06, 2016
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr (2011) 67.55
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr (2011) 6.27
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol (2000) 4.87
Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol (1978) 4.47
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry (1996) 3.42
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry (1992) 3.19
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
Tabulation of human transthyretin (TTR) variants, 2003. Amyloid (2003) 2.23
Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med (1983) 2.13
Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A (1996) 1.97
Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem (2001) 1.70
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA (2013) 1.69
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet (1991) 1.60
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol (2000) 1.34
Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol (2001) 1.24
Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett (1998) 1.23
Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem (2002) 1.22
Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol (2002) 1.14
N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica (2011) 1.06
Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) (2010) 1.03
Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol (2014) 1.00
Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta (2004) 1.00
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol (2013) 0.95
Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens Suppl (2002) 0.92
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A (2013) 0.92
Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. J Am Chem Soc (2013) 0.88
The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J Biol Chem (2004) 0.88
Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet (2003) 0.88
Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One (2009) 0.87
The Diflunisal Trial: study accrual and drug tolerance. Amyloid (2012) 0.87
An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther (2013) 0.87
Interspecies difference of luteolin and apigenin after oral administration of Chrysanthemum morifolium extract and prediction of human pharmacokinetics. Pharmazie (2013) 0.86
Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. J Struct Biol (2012) 0.84
Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. PLoS One (2009) 0.84
Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem J (2005) 0.84
Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One (2012) 0.83
Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid (2008) 0.81
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation. J Med Chem (2013) 0.80
The transthyretin amyloidoses: advances in therapy. Postgrad Med J (2015) 0.79
Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites. J Biol Chem (2015) 0.78
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma. J Med Chem (2015) 0.78
The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response. PLoS One (2015) 0.77
Bifunctional crosslinking ligands for transthyretin. Open Biol (2015) 0.77
Polychlorinated biphenyls inhibit amyloid fibril formation. Chem Biol (2004) 0.76
S-Glucuronidation of 7-mercapto-4-methylcoumarin by human UDP glycosyltransferases in genetically engineered fission yeast cells. Biol Chem (2011) 0.76
Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. Cell Host Microbe (2016) 1.53